
O. Reg. 17/17: DESIGNATED DRUGS AND STANDARDS OF PRACTICE
filed February 6, 2017 under Optometry Act, 1991, S.O. 1991, c. 35
Skip to contentontario regulation 17/17
made under the
Optometry Act, 1991
Made: November 9, 2016
Approved: February 2, 2017
Filed: February 6, 2017
Published on e-Laws: February 6, 2017
Printed in The Ontario Gazette: February 25, 2017
Amending O. Reg. 112/11
(DESIGNATED DRUGS AND STANDARDS OF PRACTICE)
1. Section 2 of Ontario Regulation 112/11 is revoked and the following substituted:
Limitations
2. Where a limitation or a route of administration is indicated with respect to a drug listed in Schedule 1, either in a sub-category heading or with respect to that particular drug, a member shall only prescribe the drug in compliance with the limitation and in accordance with the route of administration specified.
2. (1) Schedule 1 to the Regulation is amended by adding the following drug under the sub-category heading “Corticosteroids (topical)”:
difluprednate
(2) Schedule 1 to the Regulation is amended by adding the following sub-category headings and drugs under the category heading “ANTI-INFLAMMATORY AGENTS”:
Corticosteroids (topical) – for the purpose of treating conditions of the eye and adnexa
triamcinolone
Immunomodulators (topical)
cyclosporine
(3) Schedule 1 to the Regulation is amended by adding the following drug under the sub-category heading “Nonsteroidal anti-inflammatory agents (topical)”:
bromfenac
(4) Schedule 1 to the Regulation is amended by adding the following drug under the sub-category heading “Mydriatics (topical)”:
tropicamide
(5) Schedule 1 to the Regulation is amended by adding the following drugs under the sub-category heading “Antiallergic agents (topical)”:
bepotastine
tacrolimus – for the purpose of treating conditions of the eye and adnexa and for a duration not exceeding 42 days
(6) Schedule 1 to the Regulation is amended by adding the following drug under the sub-category heading “Prostaglandin analogs (topical)”:
tafluprost
(7) Schedule 1 to the Regulation is amended by adding the following drug under the sub-category heading “Carbonic anhydrase inhibitors/β-adrenergic blocking agents (topical)”:
brinzolamide/timolol
(8) Schedule 1 to the Regulation is amended by adding the following sub-category heading and drug under the category heading “ANTIGLAUCOMA AGENTS”:
Carbonic anhydrase inhibitors (oral) – to lower intraocular pressure only and a member shall immediately refer the patient to a physician or to a hospital
acetazolamide
(9) Schedule 1 to the Regulation is amended by adding the following category:
SECRETAGOGUES
Secretagogues (oral) – for Sjögren’s syndrome only and only in collaboration with a physician with whom the member has established a co-management model of care
pilocarpine
Commencement
3. This Regulation comes into force on the day it is filed.
Made by:
Council of the College of Optometrists of Ontario:
Dr. Thomas-A. Noël
President
Paula Garshowitz
Registrar
Date made: November 9, 2016